What it is
An investigational fully human monoclonal antibody against activin type II receptors, administered by intravenous or subcutaneous infusion in clinical trials.
How it works
Blocks activin type IIA and IIB receptors, antagonizing myostatin and related ligand signaling and producing increased skeletal muscle mass alongside reductions in fat mass in trial subjects.
Where it's used
Under investigation for obesity (in combination with incretin therapies) and sarcopenia-related muscle wasting in clinical trials.
Regulatory status
Not FDA-approved; investigational compound in clinical trials.
Tracking it
Bimagrumab is injectable, so two things matter in a log: when you dosed and where. Rotating sites and writing both down prevents the classic “did I already pin the left side?” problem. with a half-life of about 20 days (480 h), a dose log also lets a tracker model the relative amount still in your system between doses. for titrated compounds like this one, a log that records the dose at each step is the difference between knowing your history and guessing it.
Source
Public reference
Last reviewed 2026-06-11